Digital Diagnostics

ICS 491


Upcoming guest lectures

• November 14: Aekta Shah (Ex-Google) - Data Ethics

We may need to move around some discussion question presentations.

Digital Diagnostics





Modalities for Digital Diagnostics

Modalities for Digital Diagnostics

For each of these, think about what kinds of diseases or conditions could be diagnosed using these types of data

Sensor Analysis







Text Analysis



Vision Analysis










Audio Analysis

Convolutional DBN for audio



Exciting Research

ARTICLE OPEN



An artificial intelligence based app for skin cancer detection evaluated in a population based setting

Anna M. Smak Gregoor (b)¹, Tobias E. Sangers¹, Lytske J. Bakker², Loes Hollestein¹, Carin A. Uyl – de Groot², Tamar Nijsten¹ and Marlies Wakkee (b)^{1 🖂}

Artificial intelligence (AI) based algorithms for classification of suspicious skin lesions have been implemented in mobile phone apps (mHealth), but their effect on healthcare systems is undocumented. In 2019, a large Dutch health insurance company offered 2.2 million adults free access to an mHealth app for skin cancer detection. To study the impact on dermatological healthcare consumption, we conducted a retrospective population-based pragmatic study. We matched 18,960 mHealth-users who completed at least one successful assessment with the app to 56,880 controls who did not use the app and calculated odds ratios (OR) to compare dermatological claims between both groups in the first year after granting free access. A short-term cost-effectiveness analysis was performed to determine the cost per additional detected (pre)malignancy. Here we report that mHealth-users had more claims for (pre)malignant skin lesions than controls (6.0% vs 4.6%, OR 1.3 (95% CI 1.2–1.4)) and also a more than threefold higher risk of claims for benign skin tumors and nevi (5.9% vs 1.7%, OR 3.7 (95% CI 3.4–4.1)). The costs of detecting one additional (pre)malignant skin lesion with the app compared to the current standard of care were €2567. Based on these results, Al in mHealth appears to have a positive impact on detecting more cutaneous (pre)malignancies, but this should be balanced against the for now stronger increase in care consumption for benign skin tumors and nevi.

npj Digital Medicine (2023)6:90; https://doi.org/10.1038/s41746-023-00831-w



scientific reports



OPEN Screening COVID-19 by Swaasa Al platform using cough sounds: a cross-sectional study

Padmalatha Pentakota¹, Gowrisree Rudraraju^{2⊠}, Narayana Rao Sripada², Baswaraj Mamidgi², Charishma Gottipulla², Charan Jalukuru², Shubha Deepti Palreddy², Nikhil Kumar Reddy Bhoge², Priyanka Firmal², Venkat Yechuri², Manmohan Jain², Venkata Sudhakar Peddireddi¹, Devi Madhavi Bhimarasetty¹, S. Sreenivas¹, Kesava Lakshmi Prasad K¹, Niranjan Joshi³, Shibu Vijayan⁴, Sanchit Turaga⁵ & Vardhan Avasarala⁶


The Advent of Artificial Intelligence (AI) has led to the use of auditory data for detecting various diseases, including COVID-19. SARS-CoV-2 infection has claimed more than six million lives to date and therefore, needs a robust screening technique to control the disease spread. In the present study we created and validated the Swaasa AI platform, which uses the signature cough sound and symptoms presented by patients to screen and prioritize COVID-19 patients. We collected cough data from 234 COVID-19 suspects to validate our Convolutional Neural Network (CNN) architecture and Feedforward Artificial Neural Network (FFANN) (tabular features) based algorithm. The final output from both models was combined to predict the likelihood of having the disease. During the clinical validation phase, our model showed a 75.54% accuracy rate in detecting the likely presence of COVID-19, with 95.45% sensitivity and 73.46% specificity. We conducted pilot testing on 183 presumptive COVID subjects, of which 58 were truly COVID-19 positive, resulting in a Positive Predictive Value of 70.73%. Due to the high cost and technical expertise required for currently available rapid screening methods, there is a need for a cost-effective and remote monitoring tool that can serve as a preliminary screening method for potential COVID-19 subjects. Therefore, Swaasa would be highly beneficial in detecting the disease and could have a significant impact in reducing its spread.





COVID-19 Sounds App

Upload short recordings of cough and breathing and report symptoms to help researchers from the University of Cambridge detect if a person is suffering from COVID-19.










Remote smartphone monitoring of Parkinson's disease and individual response to therapy

Larsson Omberg ^{1,10} ^{1,10}

Remote health assessments that gather real-world data (RWD) outside clinic settings require a clear understanding of appropriate methods for data collection, quality assessment, analysis and interpretation. Here we examine the performance and limitations of smartphones in collecting RWD in the remote mPower observational study of Parkinson's disease (PD). Within the first 6 months of study commencement, 960 participants had enrolled and performed at least five self-administered active PD symptom assessments (speeded tapping, gait/balance, phonation or memory). Task performance, especially speeded tapping, was predictive of self-reported PD status (area under the receiver operating characteristic curve (AUC) = 0.8) and correlated with in-clinic evaluation of disease severity (r = 0.71; $P < 1.8 \times 10^{-6}$) when compared with motor Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Although remote assessment requires careful consideration for accurate interpretation of RWD, our results support the use of smartphones and wearables in objective and personalized disease assessments.



nature medicine

Explore content > About the journal > Publish with us >

<u>nature</u> > <u>nature medicine</u> > <u>articles</u> > **article**

Article Open access Published: 02 October 2023

Early detection of autism using digital behavioral phenotyping

Sam Perochon, J. Matias Di Martino, Kimberly L. H. Carpenter, Scott Compton, Naomi Davis, Brian

Eichner, Steven Espinosa, Lauren Franz, Pradeep Raj Krishnappa Babu, Guillermo Sapiro & Geraldine


Dawson

Dawson

Nature Medicine 29, 2489–2497 (2023) Cite this article


8629 Accesses 2 Citations 400 Altmetric Metrics

a Data collection setting and app content presentation **b** Feature extraction Face detection and Facial landmarks Head-pose estimation Gaze estimation recognition Head turn Facing forward Looking away C App features Social attention Head movement Eyebrows/mouth movement s.e./average touch length/average force Proportion of response to predictability analysis applied/popping rate name and delay Attention to speech ••••• 1 d Model training and evaluation Model development (1,000 times shuffling data splits) Performance computation Fivefold cross-validation XGBoost model Pred. Binary pred. ROC curve AUC . Youden Average Youden Youden optimal optimal o over optimal Tree N K = 1,000 1-specificity f Individualized app summary Model interpretability App feature ∑ |SHAP|(%) importance Feature value Values




Values

Some of the research from my lab





Crowdsourcing experiment interface





Rate this child's display of echolalia (does the child immediately repeat the last statement made by the parent/caregiver, for example, repeating the parent's question? Do not include repetition that is appropriate to use in conversation or that is requested by the parent, i.e. "Say, 'dog.'").


- No demonstration of echolalia. Does not repeat others' speech.
- Occasionally or rarely echoes others.
- Mixed: some regular echoing of words and phrases, but also some language.
- Mostly echoed speech.
- N/A: no speech was displayed.




























Exciting Companies









PocDoc is a digital platform – from test to app to cloud – that provides results, risk assessment and access to follow on treatment from your



Test yourself using any PocDoc tests at home at your convenience



Checks key heart health measures, including blood test in under 10 minutes



Available on iOS and Android



Clear explanation of your results, overlayed with risk factors




Real time connection to clinical advice, follow on support and potential treatments

Download App

You're 5 Minutes from Improving Your Shoulder Health


Your phone is the only tool you need to understand your current mobility.





We are Digital Diagnostics

Digital Diagnostics Inc. is a pioneering Al diagnostics company on a mission to benefit patients by transforming the accessibility, affordability, equity, and quality of global healthcare through the application of technology in the medical diagnosis and treatment process.



Diagnostic tools expedite and expand access to specialty care.



Chronic disease management supports remote patient monitoring.




Life sciences applications enable trial and therapy monitoring.










:) Affectiva

a smart eye company



DUBLICATION

Supervised Learning Approach to Remote Heart Rate Estimation from Facial Videos Following the success of researchers at the MIT Media Lab estimating t...




PUBLICATION ADVERTISING MEDIA

Predicting Online Media Effectiveness Based on Smile Responses Gathered Over the Internet
To determine whether a viewer liked a piece of media and would like t...



Measuring Voter's Candidate Preference Based on Affective Responses to Election Debates Political debates cover emotive issues that impact people's lives. T...







Google Health








AI/ML-ENABLED DEVICES OVER TIME

ROCK HEAL+H

FDA approvals and clearances from 1997–2021¹




Note: 1. 2021 includes FDA approvals and clearances for Al- and ML-enabled devices through June 17, 2021 Source: FDA list of Artificial Intelligence and Machine Learning (Al/ML)-Enabled Medical Devices as of 09/22/2021


AI/ML-ENABLED DEVICES BY THERAPEUTIC AREA

FDA approvals and clearances from 1997–2021






Note: 1. 2021 includes FDA approvals and clearances for Al- and ML-enabled devices through June 17, 2021 Source: FDA list of Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices as of 09/22/2021



U.S. DIGITAL HEALTH FUNDING AND DEAL SIZE







Next time, we will talk about digital therapeutics research and companies